Nothing new here in what has been posted, but this time the predictions are coming from within Ernst and Young from India. BD
The Indian clinical trials market is predicted to continue its growth despite the current financial climate, according to a partner at Ernst & Young India’s Healthsciences Practice.
Ajit Mahadevan told The Economic Times of India that credit restrictions will see biotechs increasingly turn to India.
This will help drive growth from its current $200m a year, to the $600m that KPMG predicted it would reach by 2010.